Cannabis Law Report

DECEMBER 5, 2021

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once certain financial milestones are met.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Cannabis Law Report

JUNE 14, 2022

Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.

Access 52

Access Therapy Clinical Trials Treatment 52

Canna Care Docs

OCTOBER 3, 2023

Conventional medication methods such as opiates may help terminal patients focus on more palliative treatment options and goals in order to better one’s comfort and overall quality of life during this time. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

PrestoDoctor

OCTOBER 11, 2023

In recent years, there has been growing interest in exploring alternative therapies for individuals with ASD. However, as part of a comprehensive treatment plan, CBD may offer a complementary approach to address some of the social symptoms associated with ASD. It is important to approach CBD as part of a comprehensive treatment plan.

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Cannabis Law Report

JULY 24, 2021

“The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MMJ Recs

DECEMBER 28, 2023

In recent years, a significant shift has occurred in the perception of medical marijuana, transforming it from a controversial substance to a recognized and, in some places, a legal form of medical treatment. Epidiolex, a CBD-based medication, has even received FDA approval for the treatment of specific seizure disorders.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JUNE 21, 2021

(OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. Press Release. Entheon Biomedical Corp. CSE: ENBI) announces agreement to acquire Lobo Genetics Inc. Press Release.

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Mitchell et al., Divito & Robert F. Johnson & Roland R. 11 × 11.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

OCTOBER 9, 2021

As traditional treatment has proven inadequate at both the individual and public health level, the Commonwealth has a responsibility to research alternative options. Please join us in cosponsoring this legislation, thank you.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. The Project.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

SEPTEMBER 23, 2022

The continued criminalization of all drugs and the people who use them increases harms to public health and safety. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

NOVEMBER 16, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 19, 2022

He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives. We look forward to his guidance in helping us bring new, THC-based investigational medications into FDA approved clinical trials. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Veriheal

APRIL 11, 2022

I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 25, 2021

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. Key Topics Covered: 1.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Core Psilocybin Facilitation Skills (16 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

OCTOBER 26, 2021

Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? Chapman has operated Chapman Pharmaceutical Consulting, Inc.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JULY 1, 2022

Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. Clinical studies are performed in people and can be controlled in various ways to understand how people respond to a treatment.

Research and Development 108

Research and Development Data THC Clinical Trials 108

The Joint Blog

JANUARY 12, 2020

Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness. Still, scientific documentation of CBD’s safety and efficacy is nearly nonexistent.

Pets 36

Pets CBD Clinical Trials Research and Development 36

The Cannigma

DECEMBER 12, 2022

Scientists are hopeful that psychedelics might have more of a curative effect when it comes to mental health than many existing treatment options; meaning that unlike most psychiatric medications, psychedelics may be able to prompt long-term changes to our mental state with only a few doses. Are psychedelics safe? 19 20 21 22 23.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Joint Blog

APRIL 17, 2020

Diminishing efficacy of these receptors over time should be considered for proper treatment. Reported adverse effect in many clinical trials included amnesia, impaired balance, disturbed attention, dizziness, lethargy, and somnolence.

Events 48

Events THC Chronic Pain Sleep 48